DDInter852 DDInter927
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Halofantrine {u} (Compound) resembles {v} (Compound) Lumefantrine
Halofantrine {u} (Compound) binds {v} (Gene) CYP2C8
Halofantrine {u} (Compound) upregulates {v} (Gene) HMOX1
Halofantrine {u} (Compound) downregulates {v} (Gene) CDC20
Halofantrine {u} (Compound) causes {v} (Side Effect) Gastrointestinal pain
Halofantrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Halofantrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iodide I-131
Halofantrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Halofantrine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Halofantrine {u} may lead to a major life threatening interaction when taken with {v} Amiodarone
Halofantrine (Compound) resembles Lumefantrine (Compound)
Halofantrine (Compound) binds CYP2C8 (Gene)
Halofantrine (Compound) upregulates HMOX1 (Gene)
Halofantrine (Compound) downregulates CDC20 (Gene)
Halofantrine (Compound) causes Gastrointestinal pain (Side Effect)
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Halofantrine may lead to a major life threatening interaction when taken with Dasatinib
Halofantrine may lead to a major life threatening interaction when taken with Amiodarone